Long-term Response in Advanced Colorectal Cancer
Long-term Response in Advanced Colorectal Cancer
A video update from Prof. Gerald Prager
A video update from Prof. Gerald Prager
Assoc. Prof. Gerald Prager
GI CONNECT expert Prof. Gerald Prager shares an update on what HCPs must consider to achieve a long-term response in advanced colorectal cancer (CRC). Watch the video and download the accompanying slides to understand:
-
How to view CRC treatment as a continuum of care
-
What to consider when making treatment decisions
-
Which treatment options are available for CRC patients, 3rd line and beyond
After completing this programme, deepen your understanding of this topic with the interactive patient case study Long-term Management of Advanced CRC from Prof. Gerald Prager and Prof. Joleen Hubbard.
Assoc. Prof. Gerald Prager
Medical Oncologist
Medical University of Vienna
Austria
Dr Gerald Prager is an Associate Professor of Medicine, Board Certified for Internal Medicine Board and Certified for Haematology and Medical Oncology. In 2009, he received his M.D. from the University of Vienna. Currently, Dr Prager is Director of the Colorectal Cancer Unit of the Department of Medical Oncology at the Medical University of Vienna. He is also a member of the ESMO 2014 Scientific Committee. The research interest of his lab focuses on (tumour-) angiogenesis via regulation of endothelial cell survival and migration by cell / extracellular-matrix interaction. Through his clinical training in haemato-oncology, he became a member of the sought-after group of medical researches. He achieved his expertise in international renowned labs at University of California, San Diego, the Norris Cancer Center, Los Angeles and the Department of Vascular Biology, Mississippi University for Women (MUW). His work is honoured by 19 international awards and resulted in publications in international highly renowned journals. Dr Prager’s young research group is embedded in an international cancer research campus associated with Medical University of Vienna (MUV).
Assoc. Prof. Gerald Prager has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:
Amgen, AstraZeneca, Bayer, BMS, Incyte, Merck Serono, MSD, Servier, Takeda
Long term response in mCRC
Video |
4 min
|
Sep 2023
This programme was made for you: your opinion matters
Share your feedback in just 4 clicks and help us to continue to create the content you need.
I agree that this educational programme:
Was valuable to me:
1/4
Has improved my knowledge of this topic:
2/4
Is likely to change my clinical practice:
3/4
Was balanced and unbiased:
4/4
download resources
This programme was made for you: your opinion matters
Share your feedback in just 4 clicks and help us to continue to create the content you need.
I agree that this educational programme:
Was valuable to me:
1/4
Has improved my knowledge of this topic:
2/4
Is likely to change my clinical practice:
3/4
Was balanced and unbiased:
4/4
Clinical Takeaways
-
Treatment of advanced colorectal cancer (CRC) should be considered as a continuum of care, and patients should be offered as many life-prolonging therapies as possible
-
Decision-making at each stage of therapy should consider patients' suitability and tolerability, tumour biomarkers and prior exposure to chemotherapies and/or targeted agents
-
There are a number of treatment options for CRC patients 3rd line and beyond that should be considered, such as regorafenib, trifluridine/tipiracil as well as consideration of clinical trials and rechallenge with chemotherapy or anti-EGFR
This educational programme is supported by an Independent Medical Education Grant from Bayer.
GI CONNECT is an initiative of COR2ED, supported by an Independent Educational Grant from Bayer.